Evidence map›Paper›PMID 28654000›Full record

ReviewInternational journal of molecular sciences2017

Long-Lived Epidermal Cancer-Initiating Cells.

Marina Youssef, Andrew Cuddihy, Charbel Darido

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Grainyhead-like (Grhl) Target Genes in Development and Cancer.International journal of molecular sciences · 2022
    Review
  5. Review
  6. The functional GRHL3-filaggrin axis maintains a tumor differentiation potential and influences drug sensitivity.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marina YoussefDepartment of Medicine, Monash University Central Clinical School, Prahran, VIC 3004, Australia. marina1youssef@hotmail.com.
Andrew CuddihyDivision of Cancer Research, Peter MacCallum Cancer Centre, Grattan Street, Parkville, VIC 3052, Australia. Andrew.Cuddihy@petermac.org.
Charbel DaridoDepartment of Medicine, Monash University Central Clinical School, Prahran, VIC 3004, Australia. charbel.darido@petermac.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-melanomatous skin cancers (NMSCs), which include basal and squamous cell carcinoma (BCC and SCC respectively), represent a significant burden on the population, as well as an economic load to the health care system; yet treatments of these preventable cancers remain ineffective. Studies estimate that there has been a 2-fold increase in the incidence of NMSCs between the 1960s and 1980s. The increase in cases of NMSCs, as well as the lack of effective treatments, makes the need for novel therapeutic approaches all the more necessary. To rationally develop more targeted treatments for NMSCs, a better understanding of the cell of origin, in addition to the underlying pathophysiological mechanisms that govern the development of these cancers, is urgently required. Research over the past few years has provided data supporting both a "bottom up" and "top down" mechanism of tumourigenesis. The "bottom up" concept involves a cancer stem cell originating in the basal compartment of the skin, which ordinarily houses the progenitor cells that contribute towards wound healing and normal cell turnover of overlying epidermal skin layers. The "top down" concept involves a more differentiated cell undergoing genetic modifications leading to dedifferentiation, giving rise to cancer initiating cells (CICs). This review explores both concepts, to paint a picture of the skin SCC cell of origin, the underlying biology, and also how this knowledge might be exploited to develop novel therapies.

Indexed as

AnimalsBasal Cell CarcinomaCarcinogenesisCarcinoma, Squamous CellCell DedifferentiationDNA-Binding ProteinsEpidermisGene Expression Regulation, NeoplasticHumansNeoplastic Stem CellsSkinSkin NeoplasmsTranscription FactorsDNA-Binding ProteinsGRHL3 protein, humanTranscription Factorscancer-initiating cell (CIC)cancer stem cell (CSC)Grainyhead-like 3 (Grhl3)interfollicular epidermis (IFE)Involucrin (IVL)squamous cell carcinoma (SCC)supra-basal epidermis

Identifiers

PMID28654000
PMCPMC5535862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.